Surrozen announces submission of IND application for SZN-8141 for the treatment of diabetic macular edema. September 08, 2026 08:30 ET | Source: Surrozen, Inc. SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) - Surrozen, Inc. (Surrozen or the Company) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration seeking to evaluate SZN-8141, a bifunctional Wnt agonist and vascular endothelial growth factor (VEGF) antagonist antibody, for the treatment of diabetic macular edema (DME). "By bringing together these mechanisms, SZN-8141 is designed to both address vascular leakage and promote retinal vascular integrity. We are excited to..." "We believe SZN-8141 has the potential to offer a differentiated approach to retinal vascular disease by combining two complementary mechanisms, activation of..." "By bringing together these mechanisms, SZN-8141 is designed to both address vascular leakage and promote retinal vascular integrity. We are excited to..." "We believe SZN-8141 has the potential to offer a differentiated approach to retinal vascular disease by combining two complementary mechanisms, activation of..." "We believe SZN-8141 has the potential to offer a differentiated approach to retinal vascular disease by combining two complementary mechanisms, activation of the Wnt pathway and inhibition of VEGF, in a single molecule," said Craig Parker, Chief Executive Officer of Surrozen. "By bringing together these mechanisms, SZN-8141 is designed to both address vascular leakage and promote retinal vascular integrity. We are excited to advance SZN-8141 into clinical development and evaluate this approach in patients with diabetic macular edema in the DUET Phase 1b/2a study." In preclinical studies, SZN-8141 demonstrated superior biological activity in reducing neovascularization and promoting retinal revascularization compared with either Wnt agonist or anti-VEGF monotherapy in a rodent model of retinal vascular disease. SZN-8141 also demonstrated greater reductions in vascular leakage than anti-VEGF therapy in a rodent model of neovascular age-related macular degeneration. SZN-8141 will be evaluated in a Phase 1b/2a clinical trial in DME called DUET, designed to assess safety, tolerability, and early signs of biological and clinical activity. Surrozen expects to initiate the DUET Phase 1b/2a study in DME patients by year-end 2026, with initial data anticipated in the second half of 2027. About SZN-8141 for Retinal Diseases Surrozen is developing SZN-8141 for the treatment of DME and neovascular age-related macular degeneration (wet AMD). SZN-8141 combines Frizzled 4 (FZD4)-mediated Wnt agonism and VEGF antagonism and has the potential to provide benefits over treatment with single mechanism agents against these targets. The current standard of care for diabetic retinopathy (including DME), retinal vein occlusion and wet AMD is intravitreal administration of anti-VEGF therapies, including monotherapies and dual-pathway agents targeting VEGF and Ang-2. In addition, Merck's MK-3000, a FZD4-mediated Wnt agonist monotherapy, has demonstrated proof of concept in DME in a clinical trial. We believe SZN-8141 has the potential to treat multiple retinopathy indications and be differentiated from existing therapies. Data generated in preclinical models of retinopathy demonstrated that SZN-8141 stimulated Wnt signaling and induced normal retinal vessel regrowth while suppressing pathological vessel growth. About Surrozen Surrozen is a biotechnology company, pioneering a new class of Wnt-based therapeutics designed to harness the power of Wnt signaling to treat sight-threatening ophthalmic conditions. Built on deep scientific expertise and a proprietary antibody-engineering platform, Surrozen develops multifunctional biologics that selectively activate Wnt signaling in combination with other key disease pathways. Our approach aims to deliver best-in-class, durable therapies that have the potential to transform patient outcomes in some of the most pressing unmet medical needs in ocular diseases. For more information, visit www.surrozen.com. Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally are accompanied by words such as "will," "plan," "intend," "potential," "expect," "could," or the negative of these words and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding Surrozen's discovery, research and development activities, in particular its development plans for its product candidates (including anticipated clinical development plans and timelines, such as the Company's plan to initiate the DUET Phase 1b/2a study in DME patients by year-end 2026, the availability of data, such as initial data from the DUET study being anticipated in the second half of 2027, the potential for such product candidates to be used to treat human disease or address unmet needs in serious eye diseases, as well as the potential benefits and potential differentiation from existing therapies of such product candidates). These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management of Surrozen and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Surrozen. These forward-looking statements are subject to a number of risks and uncertainties, including the initiation, cost, timing, progress and results of research and development activities, preclinical and clinical trials with respect to its product candidates and potential future drug candidates; the Company's ability to fund its preclinical and clinical trials and development efforts, whether with existing funds or through additional fundraising; Surrozen's ability to identify, develop and commercialize drug candidates; Surrozen's ability to successfully complete preclinical and clinical studies for its product candidates; the effects that arise from volatility in global economic, political, regulatory and market conditions; and all other factors discussed in Surrozen's Annual Report on Form 10-K for the year ended December 31, 2025, and Surrozen's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 filed with the Securities and Exchange Commission ("SEC") under the heading "Risk Factors," and other documents Surrozen has filed, or will file, with the SEC. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Surrozen presently does not know, or that Surrozen currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Surrozen's expectations, plans, or forecasts of future events and views as of the date of this press release. Surrozen anticipates that subsequent events and developments will cause its assessments to change. However, while Surrozen may elect to update these forward-looking statements at some point in the future, Surrozen specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Surrozen's assessments of any date after the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

William Blair upgrades Surrozen (NASDAQ:SRZN) to "strong-buy" August 21, 2026 Key points. * William Blair upgraded Surrozen to "strong buy," while the broader analyst consensus remains "Moderate Buy" with a $45.00 price target. Ratings include two Strong Buys, three Buys, one Hold and one Sell. * Surrozen shares opened at $23.50, down 2.1%, with a market capitalization of approximately $272.8 million. The company reported a quarterly loss of $0.41 per share, beating expectations for a $1.29 loss, and revenue of $5.0 million versus the $0.47 million forecast. * Institutional investors own 66.57% of Surrozen, while insiders own 31.74%; major shareholder TCG Crossover GP II sold 325,000 shares at an average price of $21.25. * Five stocks to consider instead of Surrozen. Surrozen (NASDAQ:SRZN - Get Free Report) was upgraded by William Blair to a "strong-buy" rating in a research report issued on Thursday,Zacks.com reports. A number of other research analysts have also recently weighed in on SRZN. HC Wainwright reissued a "buy" rating and set a $44.00 price objective on shares of Surrozen in a research note on Monday, August 10th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Surrozen in a research note on Friday, July 17th. Finally, Zacks Research upgraded Surrozen from a "strong sell" rating to a "hold" rating in a report on Tuesday, July 28th. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Surrozen currently has an average rating of "Moderate Buy" and a consensus price target of $45.00. Surrozen stock down 2.1%. Surrozen stock opened at $23.50 on Thursday. The firm has a market capitalization of $272.83 million, a PE ratio of -0.58 and a beta of 0.52. Surrozen has a 52 week low of $10.73 and a 52 week high of $35.00. The firm's 50-day simple moving average is $23.10 and its 200 day simple moving average is $25.64. Surrozen (NASDAQ:SRZN - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($1.29) by $0.88. The business had revenue of $5.00 million for the quarter, compared to analysts' expectations of $0.47 million. On average, research analysts expect that Surrozen will post -7.62 EPS for the current fiscal year. Insider activity at Surrozen. In other news, major shareholder Tcg Crossover Gp Ii, Llc sold 325,000 shares of Surrozen stock in a transaction dated Wednesday, July 22nd. The shares were sold at an average price of $21.25, for a total transaction of $6,906,250.00. Following the completion of the sale, the insider directly owned 574,047 shares in the company, valued at $12,198,498.75. The trade was a 36.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 31.74% of the stock is currently owned by company insiders. Hedge funds weigh in on Surrozen. Institutional investors and hedge funds have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. grew its stake in Surrozen by 50.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 1,500 shares of the company's stock worth $34,000 after acquiring an additional 500 shares during the period. Persistent Asset Partners Ltd purchased a new position in shares of Surrozen during the 4th quarter worth $99,000. Citadel Advisors LLC lifted its stake in shares of Surrozen by 32.8% during the 3rd quarter. Citadel Advisors LLC now owns 13,875 shares of the company's stock worth $179,000 after purchasing an additional 3,424 shares during the period. Marshall Wace LLP acquired a new stake in shares of Surrozen during the fourth quarter worth $247,000. Finally, Geode Capital Management LLC boosted its holdings in shares of Surrozen by 22.6% during the second quarter. Geode Capital Management LLC now owns 30,963 shares of the company's stock worth $277,000 after purchasing an additional 5,702 shares during the last quarter. Hedge funds and other institutional investors own 66.57% of the company's stock. About Surrozen. Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity. The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Surrozen, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Surrozen wasn't on the list. While Surrozen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Perceptive Advisors LLC makes new $6.68 million investment in Surrozen, Inc. $SRZN. August 2, 2026 Key points. * Perceptive Advisors initiated a $6.68 million position in Surrozen, purchasing 229,393 shares and acquiring approximately 1.98% of the company. Institutional investors collectively own 66.57% of SRZN. * Analyst sentiment is generally positive, with an average "Moderate Buy" rating and a $42 price target; HC Wainwright raised its target to $44, though Weiss Ratings maintained a sell rating. * Surrozen reported a significant quarterly loss of $11.65 per share versus the expected $1.09 loss, despite revenue of $5 million exceeding the $4 million consensus estimate. Insiders sold approximately $7.18 million of stock during the last quarter. * MarketBeat previews the top five stocks to own by September 1st. Perceptive Advisors LLC bought a new stake in Surrozen, Inc. (NASDAQ:SRZN - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 229,393 shares of the company's stock, valued at approximately $6,682,000. Perceptive Advisors LLC owned approximately 1.98% of Surrozen as of its most recent SEC filing. Several other institutional investors and hedge funds also recently made changes to their positions in SRZN. Millennium Management LLC grew its position in shares of Surrozen by 557.1% during the fourth quarter. Millennium Management LLC now owns 721,266 shares of the company's stock worth $16,301,000 after buying an additional 611,497 shares in the last quarter. Spruce Street Capital LP acquired a new stake in Surrozen in the fourth quarter valued at $9,764,000. Kalehua Capital Management LLC acquired a new stake in Surrozen in the fourth quarter valued at $8,705,000. Braidwell LP boosted its stake in Surrozen by 235.7% during the 4th quarter. Braidwell LP now owns 470,000 shares of the company's stock valued at $10,622,000 after acquiring an additional 330,000 shares during the last quarter. Finally, Balyasny Asset Management L.P. grew its holdings in Surrozen by 169.3% during the 4th quarter. Balyasny Asset Management L.P. now owns 190,489 shares of the company's stock worth $4,305,000 after acquiring an additional 119,757 shares in the last quarter. 66.57% of the stock is currently owned by hedge funds and other institutional investors. Insider buying and selling at Surrozen. In other Surrozen news, VP Yang Li sold 1,584 shares of Surrozen stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $33.33, for a total value of $52,794.72. Following the completion of the transaction, the vice president directly owned 17,216 shares in the company, valued at $573,809.28. The trade was a 8.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Craig C. Parker sold 4,524 shares of the company's stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $33.33, for a total value of $150,784.92. Following the transaction, the chief executive officer directly owned 16,553 shares of the company's stock, valued at $551,711.49. This trade represents a 21.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 333,144 shares of company stock worth $7,177,690 in the last quarter. 31.74% of the stock is currently owned by corporate insiders. Analyst Ratings changes. A number of brokerages have recently issued reports on SRZN. TD Cowen started coverage on shares of Surrozen in a research note on Tuesday, April 21st. They issued a "buy" rating on the stock. HC Wainwright reissued a "buy" rating and issued a $44.00 price objective (up from $36.00) on shares of Surrozen in a report on Thursday, May 7th. Weiss Ratings restated a "sell (d-)" rating on shares of Surrozen in a research note on Friday, July 17th. Finally, Zacks Research raised Surrozen from a "strong sell" rating to a "hold" rating in a report on Tuesday, July 28th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $42.00. Discover more MarketBeat Research Tools Stock Screener Tool Surrozen price performance. SRZN stock opened at $22.21 on Friday. Surrozen, Inc. has a 1-year low of $9.03 and a 1-year high of $35.00. The firm has a fifty day moving average price of $23.23 and a two-hundred day moving average price of $25.27. The firm has a market cap of $257.86 million, a price-to-earnings ratio of -0.59 and a beta of 0.51. Surrozen (NASDAQ:SRZN - Get Free Report) last issued its earnings results on Wednesday, May 6th. The company reported ($11.65) earnings per share for the quarter, missing analysts' consensus estimates of ($1.09) by ($10.56). The business had revenue of $5.00 million for the quarter, compared to the consensus estimate of $4.00 million. As a group, analysts expect that Surrozen, Inc. will post -7.2 EPS for the current fiscal year. Surrozen profile. Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity. The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Surrozen, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Surrozen wasn't on the list. While Surrozen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.